Mettl3 induced miR‐338‐3p expression in dendritic cells promotes antigen‐specific Th17 cell response via regulation of Dusp16

Abstract

AbstractPathogenic Th17 cells are critical drivers of multiple autoimmune diseases, including uveitis and its animal model, experimental autoimmune uveitis (EAU). However, how innate immune signals modulate pathogenic Th17 responses remains largely unknown. Here, we showed that miR‐338‐3p endowed dendritic cells (DCs) with an increased ability to activate interphotoreceptor retinoid‐binding protein (IRBP)1–20‐specific Th17 cells by promoting the production of IL‐6, IL‐1β, and IL‐23. In vivo administration of LV‐miR‐338‐infected DCs promoted pathogenic Th17 responses and exacerbated EAU development. Mechanistically, dual‐specificity phosphatase 16 (Dusp16) was a molecular target of miR‐338‐3p. miR‐338‐3p repressed Dusp16 and therefore strengthened the mitogen‐activated protein kinase (MAPK) p38 signaling, resulting in increased production of Th17‐polarizing cytokines and subsequent pathogenic Th17 responses. In addition, methyltransferase like 3 (Mettl3), a key m6A methyltransferase, mediated the upregulation of miR‐338‐3p in activated DCs. Together, our findings identify a vital role for Mettl3/miR‐338‐3p/Dusp16/p38 signaling in DCs‐driven pathogenic Th17 responses and suggest a potential therapeutic avenue for uveitis and other Th17 cell‐related autoimmune disorders.